Valiant Laboratories Ltd
Pharmaceuticals & Biotechnology | Small Cap
Valiant Laboratories, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, driven by a solid equity ratio and no debt. However, liquidity is poor, indicating potential difficulties in meeting short-term obligations. Efficiency is also a concern, with low turnover ratios except for days sales in inventory and receivable days, suggesting challenges in asset utilization. Growth metrics reveal declining revenue and profit, though asset growth is positive. Profitability is varied, with some positive returns but negative margins. Overall, the company's financial health presents a mixed picture, with strengths in solvency offset by weaknesses in liquidity, efficiency, and recent growth trends. It's crucial to monitor these areas to ensure sustainable performance. There is a need to address the issues with liquidity and efficiency.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio2.00
- Profitability Ratio3.00
- Efficiency Ratio1.00
- Coverage Ratio1.00
- Solvency Ratio5.00
- Liquidity Ratio2.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourNeutral
- 2 HoursNeutral
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthNeutral
Valiant Laboratories, operating within the Healthcare Services sector, shows a mixed financial performance. The company demonstrates strong solvency, driven by a solid equity ratio and no debt. However, liquidity is poor, indicating potential difficulties in meeting short-term obligations. Efficiency is also a concern, with low turnover ratios except for days sales in inventory and receivable days, suggesting challenges in asset utilization. Growth metrics reveal declining revenue and profit, though asset growth is positive. Profitability is varied, with some positive returns but negative margins. Overall, the company's financial health presents a mixed picture, with strengths in solvency offset by weaknesses in liquidity, efficiency, and recent growth trends. It's crucial to monitor these areas to ensure sustainable performance. There is a need to address the issues with liquidity and efficiency.
Overall Valuation Score
P/E RATIO (TTM)
64.80
Industry Median
23.93
Small Cap Median
23.93
P/E RATIO
-199.15
P/B RATIO
1.40
Industry Median
2.53
Small Cap Median
2.53
P/S RATIO
3.33
Industry Median
1.35
Small Cap Median
1.35
Others
PEG RATIO
0.00
EV/EBITDA RATIO
0.00
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹81.65 as on Apr 29, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company's growth ratios indicate a period of decline, with drops in revenue, operating profit, and earnings per share. However, there is positive asset growth. This suggests potential investments in future capabilities. While the asset growth is a positive sign, addressing the negative trends in revenue and profitability is critical for sustainable growth.
| Growth Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | -45.51 | -26.92 | 78.2 | |
| Operating Profit Growth Rate | -122.86 | -37.5 | -220 | |
| Earnings Per Share (EPS) Growth | -99.16 | -783.33 | 46.34 | |
| Asset Growth Rate | 61.03 | 16.91 | 15.71 | |
| Net Income Growth Rate | -100 | 50 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios show a mixed performance. While capital expenditures are well-managed, adjusted EPS, cash EPS, book value per share, and dividend per share are concerning. Enhancing earnings and book value is essential for boosting investor confidence. In the healthcare sector, balancing financial performance with investments in patient care is critical.
| Financial Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 8.79 | -0.74 | -0.73 | -0.56 |
| Cash Earnings Per Share (Cash EPS) | 9.39 | 0.47 | 0 | 0.56 |
| Book Value Per Share | 30.61 | 54.88 | 54.42 | 57.59 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 38 | 46 | 114 | 34 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios present a mixed picture. The return on capital employed and the return on equity are strong, while the gross profit margin, return on assets, operating margin, and net margin need attention. A balanced approach to improving margins and asset utilization is essential for sustainable profitability. The healthcare industry requires continuous investment in technology and infrastructure.
| Profitability Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Profit Margin | 9.88 | -5.49 | -5.26 | 0 |
| Return on Capital Employed (ROCE) | 23.57 | -2 | -1 | 1 |
| Return on Equity (ROE) | 28.71 | 0 | -0.85 | -0.96 |
| Return on Assets (ROA) | 16.43 | -2.33 | -1.25 | 1.29 |
| Operating Margin | 10.48 | -4.4 | -3.76 | 2.53 |
| Net Margin | 8.68 | 0 | -1.5 | -1.27 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios present a mixed picture. There are low turnover ratios, except for days sales in inventory and receivable days. This suggests inefficient asset utilization and working capital management. Improving these ratios could lead to substantial gains in operational effectiveness and profitability. The healthcare sector requires efficient asset management to optimize resource allocation and patient care services.
| Efficiency Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 6.96 | 3.64 | 2.77 | 1.04 |
| Inventory Turnover Ratio | 23.15 | 16.7 | 20 | 9.67 |
| Receivables Turnover Ratio | 3.76 | 2.7 | 2.25 | 2.86 |
| Days Sales in Inventory Ratio | 15.77 | 21.86 | 18.25 | 37.75 |
| Receivable Days | 97 | 135.19 | 162.22 | 127.62 |
| Capital Turnover Ratio | 2.07 | 0.58 | 0.39 | 0.7 |
Fixed Asset Turnover Ratio
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
Capital Turnover Ratio
The company's coverage ratios are very low, indicating difficulties in covering interest and dividend obligations. This suggests a need for improved profitability and cash flow management. While the healthcare industry can have varying coverage needs, maintaining adequate coverage is essential for financial stability.
| Coverage Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Interest Coverage Ratio | N/A | N/A | N/A | 1.5 |
| Equity Dividend Coverage Ratio |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company exhibits strong solvency, primarily due to a high equity ratio and no debt, indicating a solid financial foundation and low risk of financial distress. This position allows the company to have financial flexibility for future investments and growth opportunities. However, relying solely on equity may limit access to capital for expansion or strategic initiatives.
| Solvency Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Debt Ratio | 0.37 | 0.24 | 0.31 | 0.09 |
| Debt to Equity Ratio | 0.59 | 0.32 | 0.45 | 0.1 |
| Equity Ratio | 0.63 | 0.76 | 0.69 | 0.91 |
| Debt To Asset Ratio | 0.28 | 0.22 | 0.26 | 0.06 |
Debt Ratio
Debt to Equity Ratio
Equity Ratio
Debt To Asset Ratio
The company's liquidity position is weak, suggesting potential difficulties in meeting its short-term obligations. The weighted average calculation highlights consistent challenges across current, quick, and cash ratios. This necessitates a careful review of working capital management to ensure timely payments and operational stability. While the healthcare industry can face fluctuating cash flows, maintaining sufficient liquidity is vital for smooth operations.
| Liquidity Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Current Ratio | 2.5 | 6.98 | 3.18 | 1.63 |
| Quick Ratio | 2.25 | 6.65 | 3.12 | 1.27 |
| Cash Ratio | 0.02 | 3.49 | 1.23 | 0.06 |
| Operating Cash Flow Ratio | 1.08 | 0.07 | 0.02 | -0.08 |
Current Ratio
Quick Ratio
Cash Ratio
Operating Cash Flow Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Valiant Laboratories Ltd | 4.37 | -199.15 | Neutral | 6.00 | 1.02 | -3.00 |
The management effectiveness of Valiant Laboratories presents a mixed picture. A significant concern is the substantial decline in sales and profitability over the past two years, reflected in negative operating profit margins. However, the consistent promoter holding suggests confidence in the company's long-term prospects. The increasing borrowings, coupled with declining sales, raise concerns about financial leverage and the efficiency of capital allocation. While there are areas of concern, stable promoter holding provides a degree of stability. Therefore, the overall management effectiveness is rated as mixed.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 74.94% | Consistent promoter holding indicates confidence. |
| CONS | Sales Growth | -26.74% | Declining sales growth indicates challenges. |
| Operating Profit Margin (OPM) | -4% | Negative OPM reflects operational inefficiency. | |
| Borrowings | ₹122 Cr. | Increasing borrowings raise concerns about leverage. |
Financial Performance & Growth
Valiant Laboratories has demonstrated a concerning trend in its recent financial performance. Sales Growth % has declined significantly to -26.74% in March 2025. The Operating Profit Margin (OPM) has also turned negative, standing at -4% in March 2025. This indicates a struggle to maintain profitability from its core operations. The quarterly results further emphasize this decline, with OPM fluctuating and often remaining negative, particularly in Sep 2024 at -31.38%. The negative profit growth, combined with declining sales, paints a concerning picture of the company's financial health. The company's performance indicates significant challenges in sustaining growth and profitability.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Sales Growth (%) | N/A | -45.48% | -26.74% |
| OPM (%) | 11% | -5% | -4% |
Capital Efficiency & Returns
The capital efficiency and returns for Valiant Laboratories are notably weak. The Return on Capital Employed (ROCE) is -0% in March 2025. The Cash Conversion Cycle (CCC) has increased to 82 days in March 2025, indicating a longer time to convert investments into cash. The increasing Working Capital Days, which have risen to 203 in March 2025, suggest inefficiencies in managing short-term assets and liabilities. The negative ROCE and extended cash conversion cycle raise concerns about the company's ability to generate returns on its capital investments efficiently.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| ROCE (%) | N/A | -2% | -0% |
| Cash Conversion Cycle (Days) | 52 | 57 | 82 |
| Working Capital Days | 71 | 109 | 203 |
Financial Health & Prudence
Valiant Laboratories shows mixed indicators regarding its financial health and prudence. Borrowings have increased from ₹60 Cr in Mar 2023 to ₹122 Cr in Mar 2025, indicating increased leverage. Interest coverage cannot be reliably assessed due to negative operating profits in recent periods. There is no dividend payout, suggesting a focus on reinvesting earnings or managing financial constraints. While the company hasn't been consistent in sharing profits, the increasing debt levels could pose a risk if not managed carefully.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Borrowings (Cr) | 60 | 77 | 122 |
| Dividend Payout (%) | 0% | 0% | 0% |
Shareholding & Ownership Structure
The shareholding and ownership structure of Valiant Laboratories presents a relatively stable picture. The promoter holding remains consistent at 74.94% from September 2023 to March 2025, indicating sustained confidence from the company's leadership. However, FII holdings have decreased from 8.64% in September 2023 to 0.64% in March 2025, reflecting reduced foreign institutional interest. DII holdings are at 0% in March 2025.
| Metric | Sep 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|
| Promoter Holding (%) | 74.94% | 74.94% | 74.94% |
| FII Holding (%) | 8.64% | 3.48% | 0.64% |
Valiant Laboratories faces a moderate level of risk due to its declining financial performance and increasing leverage. The negative operating profit margins and inconsistent profitability, coupled with a rise in borrowings, create financial strain. The decrease in FII holdings suggests a potential lack of confidence from institutional investors. Operational inefficiencies are indicated by an increasing cash conversion cycle and working capital days.
Off-balance sheet exposure quantification
There is no specific information available regarding off-balance sheet exposures for Valiant Laboratories.
Contingent liability evaluation
There is no specific data available regarding contingent liabilities.
Accounting quality red flags
There is no specific data available regarding accounting quality red flags.
Segment performance volatility
There is no specific data available regarding segment performance volatility.
Foreign exchange or interest rate exposure
There is no specific data available regarding foreign exchange or interest rate exposure.
Regulatory compliance cost trends
There is no specific data available regarding regulatory compliance cost trends.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe